University Hospital Southampton NHS Trust
Welcome,         Profile    Billing    Logout  
 8 Trials 
7 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Gupta, Sanjay
NCT05197036: A Global Clinical Study Investigating the Safety and Effectiveness of Smith and Nephew's Porous Knee System in Patients Who Need a Total Knee Replacement Due to Degenerative Arthritis, Post-traumatic Arthritis or Inflammatory Arthritis

Active, not recruiting
N/A
299
Europe, Canada, US, RoW
Total Knee Arthroplasty, Total Knee Replacement
Smith & Nephew, Inc.
Osteoarthritis, Post-traumatic Arthritis, Rheumatoid Arthritis
12/25
12/28
Ottensmeier, Christian
HARE-40, NCT03418480: HPV Anti-CD40 RNA vaccinE

Completed
1/2
32
Europe
BNT113
University of Southampton, BioNTech SE
Human Papilloma Virus Related Carcinoma, Head and Neck Neoplasm, Cervical Neoplasm, Penile Neoplasms Malignant, Unknown Primary Tumors
11/23
01/24
CRB-601-01, NCT06603844: First-in-human Study of to Treat Patients with Advanced Solid Tumor.

Recruiting
1/2
156
Europe, US
CRB-601 monoclonal antibody, Anti-PD-1 monoclonal antibody, Immune-priming single lesion SBRT
Corbus Pharmaceuticals Inc.
Solid Tumor
11/26
12/26
ModiFY, NCT05329532: Modi-1 in Breast, Head and Neck, Ovarian, or Renal Cancer

Recruiting
1/2
144
Europe
Modi-1/Modi-1v, Pembrolizumab, MicronJet600™ microneedle device (NanoPass)
Scancell Ltd
Triple Negative Breast Cancer, Renal Cell Cancer, High Grade Ovarian Serous Adenocarcinoma, Squamous Cell Carcinoma of the Head and Neck
04/26
06/26
NEBULA, NCT05043714: Study of NG-641 in Combination With Nivolumab in Metastatic or Advanced Epithelial Tumours

Checkmark Initiation of trial in combination with NG-641
Sep 2021 - Sep 2021: Initiation of trial in combination with NG-641
Active, not recruiting
1
30
Europe, US
NG-641 in combination with Nivolumab
Akamis Bio, Bristol-Myers Squibb
Metastatic Cancer, Epithelial Tumor
08/24
12/24
MOAT, NCT04830592: A Study of NG-641 and Pembrolizumab in Squamous Cell Carcinoma of the Head and Neck

Active, not recruiting
1
36
Europe
NG-641, Pembrolizumab
Akamis Bio
Squamous Cell Carcinoma of the Head and Neck
09/24
10/24
FORTIFY, NCT05165433: Study of NG-350A Plus Pembrolizumab in Metastatic or Advanced Epithelial Tumours

Active, not recruiting
1
198
Europe, US
NG-350A plus Pembrolizumab, KEYTRUDA®
Akamis Bio, Merck Sharp & Dohme LLC
Epithelial Tumor, Metastatic Cancer
03/25
05/25
Livesey, Steven
No trials found
Diprose, Paul
No trials found
Swash, Zoe
No trials found
Painter, Sophie
No trials found
Heelan, Milly
No trials found

Download Options